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Abstract
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) has been implicated 
as a major mutagenic heterocyclic amine in the human diet and is 
carcinogenic in the rat prostate.  In order to validate PhIP induced rat prostate 
neoplasia as a model of human prostate cancer progression, we sought to 
study the earliest histologic and morphologic changes in the prostate and to 
follow the progressive changes over time.  We fed 67 male Fischer F344 5 
week old rats with PhIP (400 PPM) or control diets for 20 weeks, and then 
sacrificed animals for histomorphologic examination at age 25 weeks, 45 
weeks, and 65 weeks.  Animals treated with PhIP showed significantly_more 
inflammation (P=.002 (25wk), >.001(45wk), .016(65wk)) and atrophy 
(P=.003(25wk), >.001(45wk), .006 (65wk)) in their prostate glands relative to 
controls.  Prostatic intraepithelial neoplasia (PIN) occurred only in PhIP 
treated rats.  PIN lesions arose in areas of glandular atrophy, most often in 
the ventral prostate.  Atypical cells in areas of atrophy show loss of 
glutathione S-transferase pi  immunostaining preceding development of PIN.  
None of the animals in this study developed invasive carcinomas differing 
from previous reports.  Overall, these findings suggest that the pathogenesis 
of prostatic neoplasia in the PhIP treated rat prostate proceeds from 
inflammation to post-inflammatory proliferative atrophy to PIN.  
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Introduction
Prostate cancer is the second leading cause of cancer death for men in the US.  
Specific etiologies remain unknown, but there have been associations with 
dietary factors such as the consumption of red meat and saturated fat (ref).  
Interestingly, prostate cancer rates are extremely low in Asia, particularly in 
China (ref).  While it is not known whether inherited or environmental factors are 
primary, several associations have been made.  Emigrants from eastern 
countries to the west approach western rates for prostate cancer within one 
generation, potentially correlating with adoption of a “western diet”[1] Autopsy 
studies of American men and Chinese men show a distinct difference in 
prostatitis with extremely high rates in Americans and essentially no inflammation 
in Chinese[2-4].  Several experimental associations recently have been made 
between prostatic inflammation and prostate cancer risk[5, 6].
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) has been implicated as 
a major mutagenic heterocyclic amine in the human diet[7].  We have shown that 
PhIP forms DNA adducts in prostate epithelial cells, and induces mutations in rat 
prostate, mammary gland, and intestines when administered experimentally[8].
It has been reported that roughly 50% of Fischer F344 male rats treated with 
PhIP at one year of age have invasive prostate carcinoma[9].  No report of earlier 
pathologic lesions or associated gland changes has been produced.  The images 
of the histology of the PhIP induced prostate cancers are hard to compare to the 
histomorphology of human prostate carcinoma.  In order to characterize the 
progression of prostate neoplasia, and to compare the morphology and biology of 
the PhIP induced prostate cancers to human disease, we sought to study early 
and intermediate time points in these animals.  We also sought to study control 
animals at the same ages and housed under identical conditions.  
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Methods
Animal Treatment
Male Fischer F344 Rats (Simonsen Laboratories, Gilroy, CA) were housed at  
the AALAC-accredited Lawrence Livermore National Laboratory Animal Care  
and Use facility and treated according to the guidelines in the “Guide for Care 
and Use of Laboratory Animals (Laboratory Animal Resources, National 
Research Council) with Institutional Animal Use and Care Committee approval. 
Forty rats at 5 weeks of age were fed PhIP (Toronto Research Chemicals, 
Ontario, Canada) in the diet for 20 weeks. Animals were weighed weekly 
throughout the study. For the first 13 weeks, PhIP was fed to the animals at 
400ppm in a certified basal diet (Harlan Teklad Global 18% protein rodent diet).  
However, due to weight loss in the animals, the PhIP content was reduced to 
200ppm for the final 7 weeks. Forty controls received basal diet without the 
addition of PhIP. At 20 weeks, 10 PhIP-dosed and 10 control animals were 
euthanized. Their urogenital and other grossly abnormal tissues were isolated 
and fixed in 10% neutral buffered formalin for histological examination. The 
remaining animals were all returned to a regular basal diet with euthanasia and 
histological examination at 40 and 60 weeks after treatment  (45 and 65 weeks of 
age). Historically, it is reported that over 50% of animals have invasive tumors at 
60 weeks [10].  The purpose of using the intermediate time points, as well as 
careful examination of the non-tumorous rats at 65 weeks, was to characterize 
the pre-cancerous histomorphology. 
Histology
Necropsy tissues including  the prostate, urethra, bladder, seminal vesicles, 
testes and bulbourethral glands were collected.  Additional tissues were collected 
where possible, including intestines, lungs, liver, kidney, pancreas.  All tissues 
were fixed overnight in neutral buffered formalin and then transferred to 70% 
ethanol, before processing.  Tissues were paraffin embedded using standard 
histology protocols and sectioned at 4 microns.  The resulting sections were 
stained with hematoxylin and eosin (H & E) and examined under light 
microscopy.  Tissue blocks containing the majority of the tissues of the prostate, 
particularly ventral, dorsal and lateral glands, were identified for serial step 
sectioning.  Additional levels through these blocks were mounted on + coated 
slides (Fischer) with 5 alternating levels stained with H&E for morphologic 
analysis.
Immunohistochemistry
Immunohistochemistry was performed on the 4 micrometer sections mounted on 
+ coated slides.  Slides were incubated at 100°C in 10mM Citrate , for antigen 
retrieval.  Primary antibodies were incubated overnight at room temperature in 
PBS.  Primary antibodies were used as follows:  Ki-67 1:1000(LabVision), 
GSTP1 1:400 (Calbiochem, 354211), Cox2 1:250 (Calbiochem,236004).  
Secondary antibodies and detections were performed using the biotinylated 
secondary antibody and the EnVision HRP kit (DAKO, Carpenteria, CA) following 
the manufacturers instructions.  Histologic images were captured on a Zeiss 
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Axioskop light microscope and photographed with the Zeiss AxioCam digital 
camera. 
Quantitation
The serial step sections of ventral, dorsal, lateral, and sections of anterior 
prostate glands were examined blind to treatment group.  In each, the total 
volume of any gland presenting inflammation, atrophy, atypia, or prostatic 
intraepithelial neoplasia was estimated by adding and averaging the slide surface 
areas involved by these characteristics.  In general, percent gland affected was 
given to the nearest 5%.  Inflammation was scored if there was luminal abscess 
or if there was evident peri- or intra- epithelial infiltration of any inflammatory cells 
(mononuclear or segmented neutrophils).  Often this was accompanied by an 
increased surrounding stromal thickness.  Atrophy was defined as a flattened 
epithelial cell lining with individual cells displaying a greater lateral width than 
basal to apical height.  Areas of atypia were defined as foci of cells with 
increased nuclear size and hyperchromasia in the absence of inflammation.  
There were areas of atypia directly associated with inflammation, but these were 
not counted in the quantitative analysis.  Areas of prostatic intraepithelial 
neoplasia (PIN) were defined as multiple cell layers with loss of cellular polarity 
and with evidence of focality and proliferation. Areas of proliferation remaining in 
a single cell layer were not defined as PIN.
Statistical analysis was performed using Graph Pad Prism software version 
4.0.3.   An unpaired non-parametric t-test was applied to each data set for each 
of the quantitated characteristics.  The resulting p values are recorded above 
each pair of data sets compared, and the data is represented with range, 25th-
75th percentiles, and medians plotted as shown in Figure 1.  
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Results
Animal Treatment
During the study, the PhIP-dosed rats consistently gained less weight than the 
control animals. After 13 weeks of dosing at 400ppm, the rats began to lose 
weight. Consequently, the PhIP dose was reduced to 200ppm for the remaining 7 
weeks of dosing. After PhIP treatment was complete, the growth rate of the PhIP-
treated animals was the same as the controls, but these rats remained smaller 
than controls.  At week 20, at the end of treatment, the mean body weights of 
PhIP dosed animals were 191 (+/-30) grams compared to controls which were 
413 (+/-25) grams.  By week 40, the treated rats had gained slightly more than 
controls, with mean body weights of 287 (+/-42) grams compared to controls 479 
(+/-25) grams; and by week 60, the PhIP-dosed rats appeared to have the same 
mean growth rate as the untreated controls, though they did not “catch up” or 
grow at an accelerated rate (336 (+/- 39) grams for treated compared to 525 (+/-
37) grams for control). In addition, 10 PhIP-dosed animals and two control 
animals died or were euthanized due to deteriorating health prior to the 
termination of the study. 
Prostate Histomorphology
Inflammation in the PhIP treated rat prostate was the earliest and most obvious 
change, as compared to the control group (Figure 1a).  In the one rat that died 
during PhIP treatment, the prostatic epithelium was discontinuous with areas of 
epithelial loss or denudement.  These areas were accompanied by inflammation 
and luminal debris.  Inflammation was found in all prostatic glands, but was least 
prominent in the anterior or coagulating gland.  Inflammation persisted after 
discontinuing the PhIP treatment, and epithelial layers at all of the scheduled 
time points were intact, even in areas of luminal microabcess.  Many of the areas 
of inflammation were accompanied by a reactive stromal proliferation resulting in 
a distinct thickening of the thin muscular layer surrounding individual glands.  
These proliferations did not appear to overgrow the reactive process or to 
become neoplastic, as has been reported in some mouse models of prostate 
cancer[11].  Inflammation was seen focally in many of the control animals, but 
involved fewer glands, and was generally more mild.  Where the experimental 
animals had dense exudative luminal content, the control animals had only mild 
exudates with scattered luminal neutrophils.
Large areas of glandular atrophy, particularly affecting the ventral prostate were 
seen in all treated animals.  Non-treated animals also appeared to be prone to 
glandular atrophy, particularly in the ventral prostate, but with less area of the 
prostate involved (Figure 1b).  Interestingly, only in the treated animals was 
proliferation seen interspersed within areas of atrophy, and the PIN lesions seen 
in the later scheduled sacrificed animals (45 and 65 weeks) occurred in areas of 
atrophic ventral prostate in the majority of cases (Figure 4).  
PIN lesions seen in the PhIP treated rats were characterized by a cribriform 
architecture with well differentiated epithelial cells forming solid bridges and 
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circular apolar lumina.  The lesions filled the gland lumen, but did not show 
distension with foci of stromal interruption.  These features would be at least 
grade 2 (of 4) and most would be grade 3 (of 4) in published grading criteria for 
PIN in rodents [12].  
No invasive carcinoma was seen in any of the animals.  There were areas of 
inflammation induced stromal proliferation and high levels of inflammatory atypia 
(atypia of repair).  Consistent with the low rate of prostate neoplasia, we also 
observed a lower than expected rate of intestinal neoplasia.  Not all of the 
animals were examined, but of the 20 animals examined at least with segmental 
histology of the intestine, only one had a full fledged polypoid adenoma, and only 
two others had areas of early adenomatous changes.  
Immunohistochemistry
Ki67 staining confirmed a high rate of proliferation in the areas of PIN with a 
percentage nuclear positivity in these areas of 15-20%.  All other areas of the 
glands showed a range from 1-2% in normal non-inflamed areas to 5-10% focally 
in areas with inflammation (Figure 2B) or areas without inflammation but with 
aberrant cytologic features (Figure 3).  This is consistent also with the finding of 
mitotic figures in these foci.  There was no significant increase in apoptosis in 
these areas.
GSTpi immunostaining confirmed that the PIN lesions, specific cell populations in 
the areas of atrophy, and focal areas with atypical cells also showed loss of 
GSTpi (Figure 5).  The precise relationship of the GSTpi negative atypical cells 
and the development of PIN was difficult to estimate.  The prostate samples did 
not show the two populations in continuity, nor was there a continuous spectrum 
of lesions in between the polarized single layer of atypical cells to the fully 
developed PIN lesions. Cox2 levels were variable, but no cell foci appeared 
completely negative.
Leydig Cell Tumors
All rats in the 65 week group (both treated and controls) showed testicular Leydig 
cell hyperplasias with several in both groups with very large areas that might be 
regarded as Leydig cell tumors (Figure 6).  These were characterized by well 
differentiated Leydig cells of the testicular stroma with abundant cytoplasm and 
focal crystalloid like cytoplasmic inclusions.  This is a common finding in Fischer 
rats[13]. The testicular tubules were normal with good maturation of germ cells.  
The amount of testosterone production and serum testosterone levels is not 
known.  A few animals in both the treated and control groups at 45 weeks had 
focal mild Leydig cell hyperplasia.  Animals in the 25 week group had no 
evidence of testicular pathology.
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Discussion
For the first time, we have carefully examined the prostate pathology of the 
precancer stages in the PhIP rat model.  In our studies it seems clear that PhIP is 
capable of inducing a rapid and persistent prostatic inflammation.  The 
mechanism of inflammation induced by PhIP is not precisely clear, but appears 
to involve a specific toxicity to the prostatic epithelium.  This may result in an 
immediate disruption of the epithelial barrier and subsequent inflammation.  
However, this does not adequately explain the persistence of the inflammation.  
In some areas without inflammation an atypical proliferation is seen.  In areas 
near inflammation, this is similar to the epithelial reaction seen in any inflamed 
mucosa.  The areas that continue to display atypia and proliferation in the 
absence of inflammation suggest that there is a permanent change in the 
epithelium induced by PhIP.  It is not clear if this is the result of specific 
mutations, or selection based upon promoter methylation induced by the 
inflammatory or post-inflammatory biologic niche.  In our studies, we do show 
that there are populations of cells which down regulate GSTpi, a gene known to 
be down regulated in prostate epithelium via promoter methylation.
It was expected based upon previous reports that roughly half of the 65 week 
PhIP treated animals would have developed invasive carcinomas.  None did.  It 
may be the animals received an effectively decreased dose compared to 
previous publications.  Storage conditions and source and grade of the PhIP 
reagent were identical to those previously reported, but there may still have been 
unanticipated degradation of the chemical or a problem with the specific 
production run or lot.  We think this is unlikely in light of an obvious effect on the 
animal health (as indicated by animal weight and the 10 animals who became ill 
during treatment).  Furthermore, we have found that PhIP is very stable in 
previous HPLC analyses.  In the context of the histologic findings, however, 
additional hypotheses should be considered.  Colony and housing conditions 
may contribute to the levels of exposure of the animals to specific bacterial flora 
and these can contribute to prostatic inflammation.  In the context of our 
experiments, perhaps a cleaner or flora shifted colony resulted in decreased 
penetrance of the invasive cancer phenotype.  Regardless of the absence of 
invasive cancer, it should be noted that several animals developed definitive PIN 
lesions, and that PIN lesions are never seen in rats or mice as spontaneous 
lesions in untreated or non-genetically engineered prostate.  It is possible that the 
effective dose of PhIP in our study was higher than previous reports.  
Mechanistically, it may be that a higher dose would result in higher specific 
prostate epithelial toxicity, and that this would reduce the pool of potentially 
neoplastic cells.  This would imply that a specific subset of cells in the prostate is 
susceptible to both PhIP toxicity and PhIP initiated carcinogenesis.
It also is hard to compare the reported invasive phenotypes in the literature, 
because few histologic images are available.  In our study there were areas of 
profound inflammation with stromal reaction, sclerosis, and significant epithelial 
cytologic atypia (atypia of repair). Some of these might mimic invasion, out of the 
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context of the glandular architecture.  Further study is needed to determine if the 
PIN lesions seen do in fact progress to invasive carcinomas.  It will be useful to 
characterize the histomorphology of invasive carcinomas occurring in PhIP 
treated rats and to compare the morphology to human prostate cancers.  This 
comparative pathology is an essential part of validating the model for further 
study, including pre-clinical trials.
The finding that F344 rats have Leydig cell hyperplasia and Leydig cell testicular 
tumors may explain the overall susceptibility of this strain to prostate 
tumorigenesis. One group has compared the susceptibility across common 
laboratory strains and measured testosterone and estradiol levels.  Interestingly, 
the F344 rats had the second highest testosterone levels at 54 weeks, and the 
highest estradiol levels.  Only SHR rats (spontaneously hypertensive rats) had 
significantly higher testosterone levels than the other strains compared, and 
these and ACI rats appeared to be the most sensitive to prostate neoplasia[14].    
This remains an important consideration when modeling endocrine responsive 
tissues and cancers. 
We and others have shown that PhIP is capable of forming DNA adducts, and 
inducing DNA mutations in the F344 rat prostate[8, 9, 15, 16].  It has generally 
been proposed that low levels (relative to the experimental treatment in rats) of 
PhIP in the Western diet might induce low levels of mutations in the human 
prostate epithelium that might accumulate and confer a selective advantage on 
epithelial cells, ultimately resulting in cancer.  Other groups have proposed that 
PhIP is a potent endocrine hormone analog[17].  Several groups have used the 
rat model to test the effect of potential adduct and mutation preventing agents[8, 
18-20].  This is a highly useful surrogate endpoint which can be quantified with 
high specificity at early time points, before morphologic changes arise.  It is not 
precisely known that these adducts and mutations will lead to the progressive 
acquisition of cancer cell characteristics.  In part, it was the goal of this study to 
try to more clearly make this association.
Meanwhile, increasing evidence suggests that prostatic inflammation and the 
resulting reactive processes are highly associated with cancer risk.  The concept 
of prostatic inflammatory atrophy has been proposed to be a prostate cancer 
precursor, or at least to increase susceptibility to further changes resulting in 
prostate cancer[3, 6].  A number of molecular correlates with post-inflammatory 
atrophic morphology have been established, including promoter methylation and 
gene silencing for GSTpi and Cox2[5, 19, 21, 22].  We have shown that benign 
prostate lesions are sometimes accompanied by changes in apoptosis mediator 
proteins [22].
Our interest in PhIP administration in rodents as a model of human prostate 
carcinogenesis is chiefly based in clinical epidemiology. High meat and fat in the 
western diet, and particularly in African Americans, may influence both the 
development and progression of prostate cancer.  We have previously 
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demonstrated the exquisite sensitivity of the prostate to PhIP.  At a dose 
equivalent to one overcooked hamburger fed to the F344 rat, DNA adducts can 
be detected in the prostate[8].  Our data suggests that the PhIP treated rat will 
also help to characterize the role of prostate inflammation in cancer initiation.  In 
summary, we have shown that the PhIP treated rat is a useful model of human 
disease suitable for testing prevention strategies targeting either DNA adduct 
formation or prostate inflammation.
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Figure Legends
Figure 1.  Quantified changes in PhIP and Control Prostate Glands.  Overview of 
histologic changes in the PhIP treated (solid bars) and control (hatched bars) rats.  The 
median (horizontal line), 25th to 75th percentile (column boxes) and  range (tail bars) of 
percent of prostate glands involved is plotted for groups at each time point (25, 45, and 
65 weeks of age). An unpaired nonparametric t-test was applied to the groups at each 
time and the resulting p values are shown above the data bars. The t-test could not be 
applied to the PIN data because all of the values in many of the columns were zero.  The 
percentages of the glands showing inflammation is shown in panel A., atrophy in panel 
B, atypia in panel C, and prostatic intraepithelial neoplasia in panel D.
Figure 2. Atypical Proliferations Arise in Inflamed Prostate. Within areas of markedly 
inflamed prostate, foci of proliferative epithelium are seen.  Low power view of the dorsal 
and lateral prostate (A) shows a segmental area of inflammation (Infl) and another area 
of atrophy (Atr).  The urethra (U) is at the top right, and the box indicates the location of 
the high magnification seen in (B).  The high magnification shows epithelial proliferation 
with cellular loss of polarity and cytologic atypia.
Figure 3. PhIP Induces Prostate Epithelial Proliferation.  The PHIP treated prostate 
shows abnormal proliferation with mitoses indicated by the arrows as compared to the 
control vehicle treated animal on the right.  Both panels are ventral prostate glands from 
rats.  Images from formalin fixed paraffin embedded tissue 4 micron sections stained 
with hematoxylin and eosin, obtained on a Zeiss Axioskop equipped with the Zeiss 
AxioCam digital camera using the Axiovision acquisition software. Scale bars indicate 
actual size (lower right of each panel).
Figure 4. PIN arises in atrophy in PHIP treated rat prostate. Within the atrophic 
glands, occasional areas of proliferation with loss of polarity and cells forming cribriform 
spaces and Roman bridges are seen.  The high proliferation of these areas is confirmed 
by the Ki67 immunostain (B) showing a marked increase in percent cell staining (nuclear 
stain) in these regions.
Figure 5. Atypical cells in PHIP treated rat prostate show loss of GSTp1, Cox2 is 
roughly unchanged.  The atypical cells shown (arrows in panel A) have abundant 
cytoplasm and nuclei with single prominent nucleoli.  Basal cells can be seen 
interspersed among these cells and are highlighted by the GST immunostain (B). Cox2 
(C)may be slightly reduced in the same cells, but is detected by the immunostain. 
Figure 6. F344 Rats Develop Leydig Cell Hyperplasia. Rats in both the control and 
PhIP treated groups developed Leydig cell hyperplasia with high penetrance.  Patchy 
areas of Leydig cell hyperplasia, varying in size were seen in a majority of animals at the 
65 weeks of age time point.  This example shows a relatively large patch of Leydig cells 
(Ley) adjacent to two seminiferous tubules (Tub).
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